Key secondary endpoint:
composite of CV death, MI, or stroke1,2

Repatha® Outcomes study key secondary endpoint Repatha® Outcomes study key secondary endpoint
Repatha® is the first and only PCSK9 inhibitor FDA-approved to reduce CV risk in a wide range of patients with established CVD—including MI, stroke, and PAD1,2
  • Primary composite endpoint: HR 0.85 (95% Cl, 0.79-0.92; P < 0.0001)1

  • Key secondary composite endpoint: HR 0.80 (95% Cl, 0.73-0.88; P < 0.0001)1

  • Relative risk reductions for the primary and secondary composite endpoints were driven by a reduction in the risk of MI: HR 0.73 (95% Cl, 0.65-0.82), stroke: HR 0.79 (95% Cl, 0.66-0.95) and coronary revascularization: HR 0.78 (95% Cl, 0.71-0.86)1

Observed HR for CV death: 1.05 (95% Cl, 0.88-1.25) and hospitalizations due to unstable angina:
0.99 (95% Cl, 0.82-1.18)1

At Week 48, the median LDL-C was 26 mg/dL.1

ARR = absolute risk reduction; HR = hazard ratio; MI = myocardial infarction; PAD = peripheral artery disease; defined as a history of intermittent claudication (with or without supporting vascular investigations) or previous peripheral arterial revascularization procedure, amputation, or aneurysm repair; RRR = relative risk reduction.